Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi CEO Paul Hud­son of­floads two port­fo­lios to Ger­man phar­ma com­pa­ny in con­tin­ued ef­fort to prune prod­ucts

Sanofi warned ear­li­er this year that some se­ri­ous cuts were in or­der. CEO Paul Hud­son made good on that promise this week, prun­ing more than a dozen mar­ket­ed prod­ucts.

Ger­many-based Neu­rax­pharm re­vealed yes­ter­day that it struck a deal for Sanofi’s CNS and pain and vas­cu­lar dis­ease port­fo­lios. While the com­pa­nies are keep­ing the fi­nan­cial terms un­der wraps for now, Neu­rax­pharm did say it’s swal­low­ing 17 prod­ucts rep­re­sent­ing 38 brands, in­clud­ing neu­rolep­tics Noz­i­nan and Tiapri­dal, anx­i­ety med Tranx­ene and an­tipsy­chotics Dog­matil and Largac­til.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.